Pulmonary drug delivery systems are used to deliver aerosols directly to epithelial cells and respiratory epithelium through inhalation. The systems include devices such as inhalers and nebulizers for delivering drugs to the lungs to treat patients affected by respiratory diseases. Pulmonary drug delivery devices are based on diverse delivery mechanisms and contain various drug formulations. Asthma, chronic obstructive pulmonary diseases (COPD), acute respiratory tract infections, allergic rhinitis, and cystic fibrosis are major respiratory diseases that require the use of drug delivery devices. The increasing burden of respiratory diseases and growing strategic initiatives by companies favor the pulmonary drug delivery systems market growth. The pulmonary drug delivery systems market trends include the advancements in inhaler technologies that will favor the growth of the market in the future.
Companies operating in the pulmonary drug delivery systems market constantly focus on strategic developments such as collaboration, agreements, partnerships, and new product launches. These strategies help them improve their sales, increase their geographic reach, and enhance their capacities to serve a greater than existing customer base. The new product launches are mainly directed toward increased security, user-friendly features, better dosing capabilities, etc., to attract a large patient base. Following are a few noteworthy developments in the pulmonary drug delivery systems market:
Thus, the growing number of strategic developments and product launches by the companies to remain competitive in the market propels the pulmonary drug delivery systems market growth.
The pulmonary drug delivery systems market analysis has been carried out by considering the following segments: product, indication, distribution channel, end user, and geography. In terms of product, the market is segmented into dry powder inhalers, nebulizers, and metered dose inhalers. By indication, the market is classified into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and e-commerce. Based on end user, the market is bifurcated into hospitals & clinics and homecare. The scope of pulmonary drug delivery systems market report covers North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
The pulmonary drug delivery systems market, by product, is categorized into dry powder inhalers, nebulizers, and metered dose inhalers. The dry powder inhalers segment held a significant market share in 2023. It is anticipated to record the highest CAGR in the market during 2023–2031.
In terms of indication, the pulmonary drug delivery systems market is classified into chronic obstructive pulmonary diseases, asthma, cystic fibrosis, and others. The chronic obstructive pulmonary diseases segment held a significant market share in 2023 and is projected to register the highest CAGR during 2023–2031.
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held a significant pulmonary drug delivery systems market share in 2023. The e-commerce segment is expected to register the highest CAGR during 2023–2031.
Based on end user, the pulmonary drug delivery systems market is bifurcated into hospitals & clinics and homecare. The hospitals & clinics segment held a significant market share in 2023. The homecare segment is estimated to register a higher CAGR during 2023–2031.
Geographically, the pulmonary drug delivery systems market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America held a significant share of the market. In 2023, the US held the largest share of the market in the region. The market growth in North America is attributed to the rising incidence of respiratory diseases such as asthma, COPD, and others; increasing geriatric population; growing demand for diagnostic devices; and the strong presence of key market players. According to the Centers for Disease Control and Prevention (CDC), 2020, about 5.0% of adults are diagnosed with COPD or chronic bronchitis in the US. About 25 million people are affected by asthma, and 14.8 million have COPD. In addition, the Canadian Nurse Association estimated that ~3 million people in Canada suffer from one of serious respiratory diseases such as COPD, cystic fibrosis, asthma, and occupational lung diseases.
According to the Canadian Lung Association, respiratory diseases are responsible for the third highest share of hospitalizations, and approximately one in five people in Canada suffer from serious respiratory diseases, such as asthma, COPD, lung cancer, tuberculosis, cystic fibrosis, and respiratory distress syndrome. The rising number of patients suffering from various respiratory diseases propels the demand for innovative and effective pulmonary drug delivery systems such as metered dose inhalers or nebulizers.
The regional trends and factors influencing the Pulmonary Drug Delivery Systems Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Pulmonary Drug Delivery Systems Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 49.71 Billion |
| Market Size by 2031 | US$ 73.14 Billion |
| Global CAGR (2023 - 2031) | 4.9% |
| Historical Data | 2021-2023 |
| Forecast period | 2023-2031 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Pulmonary Drug Delivery Systems Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Pulmonary Drug Delivery Systems Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The pulmonary drug delivery systems market report includes company positioning and concentration to evaluate the performance of competitors in the market. As per company press releases, below are a few initiatives taken by key players operating in the market:
The pulmonary drug delivery systems market forecast can help stakeholders plan their growth strategies. AstraZeneca, GlaxoSmithKline Plc, Novartis AG, Koninklijke Philips NV, Boehringer Ingelheim International GmbH, Cipla Inc., OMRON Corp., PARI GmbH, Glenmark Pharmaceuticals, and Gilbert Technologies are among the prominent players in the market. These companies focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.
The List of Companies - Pulmonary Drug Delivery Systems Market
The factors driving the growth of the pulmonary drug delivery systems market include the increasing burden of respiratory diseases and growing strategic initiatives by companies. However, regulatory issues associated with the approval of pulmonary drug delivery systems hampers the growth of the pulmonary drug delivery systems market.
The global pulmonary drug delivery systems market is segmented based on product, indication, distribution channel, and end user. The pulmonary drug delivery systems market, by product, is categorized into dry powder inhalers, nebulizers, and metered dose inhalers. The dry powder inhalers segment held a significant market share in 2023 and is anticipated to record the highest CAGR in the market during 2023–2031.
The pulmonary drug delivery systems market was valued at US$ 49.71 billion in 2023.
The pulmonary drug delivery systems market is expected to be valued at US$ 73.14 billion in 2031.
The pulmonary drug delivery systems market majorly consists of the players, including AstraZeneca, GlaxoSmithKline Plc, Novartis AG, Koninklijke Philips NV, Boehringer Ingelheim International GmbH, Cipla Inc., OMRON Corp., PARI GmbH, Glenmark Pharmaceuticals, and Gilbert Technologies.
Pulmonary drug delivery refers to the systems that target the delivery of aerosols directly to epithelial cells and respiratory epithelium through inhalation. These systems deliver the drug to the lungs to treat respiratory diseases. It is one of the most preferred drug delivery routes and a noninvasive technique with a large surface area of absorption and blood circulation.